Centessa Pharma Confirms Ordinary Shares Listed on Nasdaq

Ticker: CNTA · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1847903

Centessa Pharmaceuticals PLC 8-K Filing Summary
FieldDetail
CompanyCentessa Pharmaceuticals PLC (CNTA)
Form Type8-K
Filed DateJan 9, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, stock-listing

TL;DR

**Centessa Pharma's ordinary shares are officially listed on Nasdaq under CNTA.**

AI Summary

Centessa Pharmaceuticals plc filed an 8-K on January 9, 2024, to update its registration of securities. The company clarified that its Ordinary shares, with a nominal value of £0.002 per share, are traded on the Nasdaq Stock Market, LLC under the symbol CNTA. This filing is important for investors as it confirms the specific class of shares registered and where they are publicly traded, ensuring transparency and proper regulatory compliance for those holding or considering buying CNTA stock.

Why It Matters

This filing clarifies the specific class of shares registered and their listing exchange, which is crucial for investors to understand what they are buying and where it trades.

Risk Assessment

Risk Level: low — This filing is a routine administrative update and does not indicate any new financial or operational risks for the company.

Analyst Insight

Investors should note this filing as a confirmation of the company's listed securities and trading venue, ensuring their records align with the official registration details for CNTA shares on Nasdaq.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of Centessa Pharmaceuticals plc's 8-K filing dated January 9, 2024?

The 8-K filing by Centessa Pharmaceuticals plc on January 9, 2024, is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically addressing Regulation FD Disclosure and Financial Statements and Exhibits. It primarily serves to confirm the registration of its securities.

What specific class of securities is registered by Centessa Pharmaceuticals plc according to this filing?

According to the filing, the specific class of securities registered by Centessa Pharmaceuticals plc are "Ordinary shares, nominal value £0.002 per share."

On which exchange are Centessa Pharmaceuticals plc's Ordinary shares traded?

Centessa Pharmaceuticals plc's Ordinary shares are registered and traded on the Nasdaq Stock Market, LLC.

What is the trading symbol for Centessa Pharmaceuticals plc's Ordinary shares?

The trading symbol for Centessa Pharmaceuticals plc's Ordinary shares is CNTA.

What is the nominal value of each Ordinary share of Centessa Pharmaceuticals plc?

The nominal value of each Ordinary share of Centessa Pharmaceuticals plc is £0.002 per share.

Filing Stats: 595 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-01-09 07:56:10

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Centessa Pharmaceuticals plc (the "Company") from time to time presents and/or distributes slide presentations to the investment community at various industry and other conferences to provide updates and summaries of its business. The Company is posting a copy of its current corporate slide presentation to the "Investors" portion of its website at www.centessa.com/events-presentations. These slides are attached to this Current Report on Form 8-K as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing .

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. 99.1 Corporate Presentation pre pared as of January 9, 2024 104 Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 9, 2024 By: /s/ Saurabh Saha Name: Saurabh Saha, M.D., Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing